Sökning: id:"swepub:oai:lup.lub.lu.se:8e63c41e-ff9d-4bf8-84eb-4b2033d1da9e" >
Switch to Biologica...
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
-
- Norlin, Jenny M, 1982- (författare)
- Umeå universitet,Dermatologi och venereologi
-
- Steen Carlsson, Katarina (författare)
- Lund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,Department of Clinical Sciences, Skåne University Hospital, Clinical Research, Lund University, Malmö, Sweden
-
- Persson, Ulf (författare)
- Lund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,Institute for Economic Research, School of Economics, Lund University, Lund, Sweden
-
visa fler...
-
- Schmitt-Egenolf, Marcus, 1966- (författare)
- Umeå universitet,Dermatologi och venereologi
-
visa färre...
-
(creator_code:org_t)
- 2013-01-16
- 2012
- Engelska.
-
Ingår i: Dermatology. - : S. Karger AG. - 1421-9832 .- 1018-8665. ; 225:4, s. 326-332
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://www.karger.c...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare. Objective: To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents. Methods: Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Outcomes of biological-naive patients who switched to a biological agent (n = 267) were analysed before switch and at the first follow-up. Results: Patients significantly improved in EQ-5D, DLQI and PASI (p < 0.001). Patients with DLQI >= 10 and/or PASI >= 10 had the greatest benefits from biological agents in terms of EQ-5D. Conclusions: Patients with moderate to severe psoriasis benefit from biological agents in clinical practice; the patients with the highest benefits were those with high pretreatment PASI and DLQI scores. Copyright (c) 2013 S. Karger AG, Basel
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Nyckelord
- Biological agents
- Psoriasis
- EQ-5D
- DLQI
- PASI
- Register
- Biological agents
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas